As biotechnology industry expands, so does the need for strategic marketing approaches to reach investors, regulatory bodies, healthcare providers, and consumers…read more
The biotechnology industry is experiencing rapid advancements in gene editing, personalized medicine, synthetic biology, and biopharmaceuticals. As the industry expands,…
Yesterday, the U.S. Supreme Court heard oral argument in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., No. 24-889, a…
For years, parallel proceedings at the Patent Trial and Appeal Board (PTAB) were the near-automatic response of a defendant in…
Last year we discussed the implications of the Supreme Court’s choice not to review the Federal Circuit’s SnapRays decision for…
In a decision that is quickly gaining attention, the Federal Circuit held that the district court abused its discretion by…
The Supreme Court’s decision to review Hikma Pharmaceuticals USA Inc. v. Amarin Pharma Inc. places renewed attention on a familiar…
In the past few months, the U.S. Patent and Trademark Office (“PTO”) Acting Director has made substantial changes to the…
Sign in to your account